Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Share-based Compensation (2018 - 2025)

Historic Share-based Compensation for Organogenesis Holdings (ORGO) over the last 8 years, with Q3 2025 value amounting to $3.1 million.

  • Organogenesis Holdings' Share-based Compensation rose 1301.62% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.9 million, marking a year-over-year increase of 1802.45%. This contributed to the annual value of $10.6 million for FY2024, which is 1758.56% up from last year.
  • Latest data reveals that Organogenesis Holdings reported Share-based Compensation of $3.1 million as of Q3 2025, which was up 1301.62% from $2.5 million recorded in Q2 2025.
  • In the past 5 years, Organogenesis Holdings' Share-based Compensation registered a high of $3.4 million during Q1 2025, and its lowest value of $698000.0 during Q1 2021.
  • For the 5-year period, Organogenesis Holdings' Share-based Compensation averaged around $2.1 million, with its median value being $2.3 million (2023).
  • Its Share-based Compensation has fluctuated over the past 5 years, first soared by 23397.13% in 2021, then plummeted by 101.25% in 2025.
  • Quarter analysis of 5 years shows Organogenesis Holdings' Share-based Compensation stood at $1.1 million in 2021, then skyrocketed by 71.28% to $1.9 million in 2022, then rose by 27.55% to $2.4 million in 2023, then grew by 22.19% to $2.9 million in 2024, then rose by 6.02% to $3.1 million in 2025.
  • Its last three reported values are $3.1 million in Q3 2025, $2.5 million for Q2 2025, and $3.4 million during Q1 2025.